Get the Stockscreener App
0.0238
18.42%
0.0037
Geovax Labs Inc stock is traded at $0.0238, with a volume of 20,378.
It is up +18.42% in the last 24 hours and down -32.19% over the past month.
GeoVax Labs, Inc., a clinical-stage biotechnology company, develops human vaccines and immunotherapies against infectious diseases and solid tumor cancers using modified vaccinia ankara virus-like particle vaccine platform. It is developing various preventive vaccines against (COVID-19), human immunodeficiency virus (HIV); Zika virus; malaria; and hemorrhagic fever viruses, such as Ebola, Sudan, Marburg, and Lassa, as well as therapeutic vaccines for HIV, chronic Hepatitis B infections, and solid tumor cancers. The company is developing GEO-CM04S1, a vaccine candidate that is in Phase 2 clinical trial for the treatment of preventive COVID-19; Gedeptin, a novel patented product/technology for the treatment of solid tumors, and Phase 1/2 clinical trial for the treatment of advanced head and neck squamous cell carcinoma; and GEO-CM02, a pan-coronavirus vaccine. In addition, it is also developing GEO-ZM02, a vaccine candidate, which is in preclinical trial for the treatment of GEO-ZM02, a vaccine candidate, which is in preclinical trial for the treatment of Zika; GEO-MM02 treatment for malaria; GEO-EM01 for the treatment of fever viruses, such as Ebola, Sudan, and Marburg; GEO-LM01 for the treatment of Lassa fever. GeoVax Labs, Inc. has collaboration and partnership agreements with the National Institute of Allergy and Infectious Diseases of the National Institutes of Health; U.S. Department of Defense; Emory University; and the Burnet Institute. GeoVax Labs, Inc. was incorporated in 1988 and is headquartered in Smyrna, Georgia.
See More
Previous Close:
$0.0201
Open:
$0.0238
24h Volume:
20,378
Relative Volume:
1.10
Market Cap:
$N/A
Revenue:
-
Net Income/Loss:
-
P/E Ratio:
-
EPS:
-
Net Cash Flow:
-
1W Performance:
-18.76%
1M Performance:
-32.19%
6M Performance:
-80.18%
1Y Performance:
-70.97%
1-Day Range:
$0.0202
$0.0238
1-Week Range:
$0.02
$0.038
52-Week Range:
$0.0141
$0.65
Geovax Labs Inc Stock (GOVXW) Company Profile
Name
Geovax Labs Inc
Sector
Industry
Phone
678 384 7220
Address
1900 Lake Park Drive, Suite 380, Smyrna
Compare GOVXW with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
GOVXW
Geovax Labs Inc
|
0.0238 | 0 | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
473.78 | 117.98B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
567.37 | 58.10B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
318.32 | 42.26B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
566.50 | 33.42B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
253.25 | 26.08B | 3.81B | -644.79M | -669.77M | -6.24 |
Geovax Labs Inc Stock (GOVXW) Latest News
GeoVax Labs (NASDAQ:GOVX) Upgraded by Wall Street Zen to “Hold” Rating - Defense World
Why Did GeoVax Labs Inc. (GOVX) Soar 10.34%? - AInvest
Roth MKM Keeps Their Buy Rating on GeoVax Labs (GOVX) - The Globe and Mail
Vaccine Co. Secures European Regulatory Breakthrough Potential - streetwisereports.com
GeoVax Labs (NASDAQ:GOVX) Cut to “Sell” at Wall Street Zen - Defense World
GeoVax Labs Announces $6 Million Public Offering - The Globe and Mail
GeoVax Responds to Growing Mpox Threat With Expedited EU Pathway and Platform Aligned to U.S. Biodefense Objectives - Yahoo Finance
GeoVax Announces $6 Million Public Offering to Advance Immunotherapies and Vaccines - citybuzz -
GeoVax Announces Issuance of Patent Covering Novel Vaccine Construct for Preventing Malaria Infection - Yahoo Finance
GeoVax Comments on FDA Approval of Keytruda(R) in Head and Neck Cancer, Underscoring Potential for Gedeptin(R) Combination Therapy - Yahoo Finance
Financial Health Check: Examining Geovax Labs Inc (GOVX)’s Key Ratios - DWinneX
Why Beyond Air Shares Are Trading Lower By Over 23%; Here Are 20 Stocks Moving Premarket - Benzinga
Geovax Labs Inc Inc. (GOVX) Price Performance: Is It Undervalued or Overvalued? - investchronicle.com
GeoVax Labs (GOVX) Gains Positive EMA Feedback, Potential Speedier Approval | GOVX Stock News - GuruFocus
GeoVax Highlights Positive Immune Response Results From GEO-CM04S1 in CLL Patients at the European Hematology Association 2025 Meeting - Yahoo Finance
GeoVax Advances Toward European Approval for Mpox and Smallpox Vaccine with EMA's Support - citybuzz -
GeoVax Labs’ (GOVX) “Buy” Rating Reaffirmed at D. Boral Capital - Defense World
GeoVax Labs (GOVX) Issues New Stock Units with Warrants | GOVX Stock News - GuruFocus
GeoVax Labs (GOVX) Gains EMA Approval for Phase 3 Vaccine Trial | GOVX Stock News - GuruFocus
GOVX: Geovax Labs Receives Buy Rating from Analyst | GOVX Stock News - GuruFocus
GeoVax Receives Favorable European Regulatory Guidance Supporting Streamlined Development Pathway for GEO-MVA - Yahoo Finance
GeoVax to Showcase Innovative Vaccines and Therapies at BIO International Convention 2025 - citybuzz -
GeoVax to Participate in BIO International Convention 2025 - Yahoo Finance
Geovax highlights progress on mpox vaccine and COVID-19 trial advancements - MSN
GeoVax Advances GEO-MVA Vaccine Development Amid WHO's Mpox Emergency Declaration - citybuzz -
GeoVax Responds to WHO's Fourth Declaration of Mpox as a Global Public Health Emergency - Yahoo Finance
Robinhood Markets, Inc. Reports May 2025 Operating Data - The Globe and Mail
GeoVax to Showcase Positive Immune Response Data for GEO-CM04S1 in CLL Patients at EHA 2025 Congress - citybuzz -
GeoVax Announces Upcoming Presentation at the European Hematology Association 2025 Congress Highlighting Positive Immune Response Data for GEO-CM04S1 in CLL Patients - Yahoo Finance
42,275 Shares in GeoVax Labs, Inc. (NASDAQ:GOVX) Acquired by Citadel Advisors LLC - Defense World
GeoVax’s Multi-Antigen COVID-19 Vaccine Candidates Show Promise Against Variants - citybuzz -
GeoVax Highlights Broad Cross-Protective Immunity of Multi-Antigen COVID-19 Vaccine Candidates at Keystone Symposia - Yahoo Finance
Northern Trust Corp Invests $29,000 in GeoVax Labs, Inc. (NASDAQ:GOVX) - Defense World
GeoVax to Showcase Innovative COVID 19 Vaccine Data at the Keystone Symposia on Vaccinology - Yahoo Finance
GeoVax Labs, Inc. (NASDAQ:GOVX) Receives Average Recommendation of “Buy” from Analysts - Defense World
GeoVax Congratulates Bipartisan Senate Action to Onshore Critical Medical Manufacturing - Yahoo Finance
GeoVax Labs (NASDAQ:GOVX) Shares Up 6.9% – Should You Buy? - Defense World
GeoVax Commends FDA's Shift to Risk-Based COVID-19 Vaccination Guidance - Yahoo Finance
GeoVax Applauds EQUIP-A-Pharma Initiative, Reinforces Commitment to Domestic Vaccine Manufacturing and Biodefense Innovation - Yahoo Finance
GeoVax Reaffirms Urgent Need for Multi-Antigen COVID-19 Vaccines as CDC Shifts Recommendations - Yahoo Finance
What caused GOVX's Q2 2024 profit turnaround? - AInvest
GeoVax Labs (GOVX) Projected to Post Earnings on Tuesday - Defense World
GeoVax Highlights Dual Protective Potential of GEO-CM04S1 Following Presentation at the AAI Annual Meeting 2025 - Yahoo Finance
GeoVax Strengthens Patent Portfolio for Innovative Cancer Therapy Approach - citybuzz -
GeoVax Expands Gedeptin(R) Patent Portfolio - Yahoo Finance
GeoVax Applauds White House Executive Order Supporting U.S. Pharmaceutical Manufacturing; Highlights Progress in Domestic MVA Vaccine Production - Yahoo Finance
MarketsMedicine Hat News - FinancialContent
GeoVax Announces Positive Interim Data Review for Phase 2 Clinical Trial of COVID-19 Vaccine Booster in Patients with Chronic Lymphocytic Leukemia - ADVFN
D. Boral Capital Cuts GeoVax Labs (NASDAQ:GOVX) Price Target to $9.00 - Defense World
GeoVax Labs, Inc. (NASDAQ:GOVX) Given Consensus Recommendation of “Buy” by Analysts - Defense World
Form 8-KCurrent report - ADVFN
Geovax Labs Inc Stock (GOVXW) Financials Data
There is no financial data for Geovax Labs Inc (GOVXW). Check out other stocks for more information.
Revenue
Net Income
Cash Flow
EPS
0.28%
2.13%
Cap:
|
Volume (24h):